NCT06530810View on ClinicalTrials.gov

Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

May 8, 2026

Study Completion Date

May 8, 2028

Conditions
Chronic Myelogenous LeukemiaCML Chronic PhaseCML Accelerated Phase
Interventions
DRUG

HS-10382+Flumatinib

Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY